Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €10.63 EUR
Change Today +0.011 / 0.10%
Volume 0.0
VM4 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:35 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VM4) Snapshot

Open
€10.69
Previous Close
€10.62
Day High
€11.31
Day Low
€10.58
52 Week High
12/29/14 - €12.40
52 Week Low
10/13/14 - €6.51
Market Cap
449.6M
Average Volume 10 Days
31.0
EPS TTM
--
Shares Outstanding
42.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VM4)

vanda pharmaceuticals inc (VM4) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VM4) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

105 Employees
Last Reported Date: 07/31/15
Founded in 2002

vanda pharmaceuticals inc (VM4) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $580.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

vanda pharmaceuticals inc (VM4) Key Developments

Vanda Pharmaceuticals, Inc. Announces Pivotal Trial Results Related to Patient Entrainment in the August Issue of the Lancet

Vanda Pharmaceuticals Inc. announced publication of pivotal trial results related to patient entrainment in the August issue of The Lancet. The published trial results are from the SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Sleep-Wake Disorder (Non-24)) Phase III studies of HETLIOZ® (tasimelteon), a circadian regulator for the treatment of individuals suffering from Non-24. Non-24 is a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception, and consequently cannot entrain (synchronize) their master body clock to the 24-hour day. Tasimelteon, marketed under the tradename HETLIOZ®, is currently approved for use in the United States and in the European Union. In the SET study, HETLIOZ® achieved the primary endpoints of entrainment of the melatonin rhythm as compared to placebo and clinical response as measured by entrainment plus a score of greater than or equal to 3 on the Non-24 Clinical Response Scale. HETLIOZ® also demonstrated significant improvement versus placebo across a number of sleep and wake parameters including measures of total sleep time, daytime sleep duration, and timing of sleep, as well as in the Clinical Global Impression of Change, an overall global functioning scale. In treated patients, daytime sleep decreased by 46 minutes per day in the worst 25% of days and nighttime sleep increased by 57 minutes per day during the worst 25% of nights. The RESET study demonstrated that continued treatment with 20mg of HETLIOZ® is required to maintain entrainment of the master body clock as measured by melatonin and cortisol circadian rhythms in individuals with Non-24. Patients treated with HETLIOZ® maintained their clinical benefits while patients who received placebo showed significant deterioration in measures of nighttime sleep, daytime sleep and timing of sleep. Furthermore, discontinuation of HETLIOZ® resulted in a rapid loss of circadian entrainment and a return to non-entrained circadian rhythms, reinforcing the importance of chronic therapy. Twenty-four-hour biological rhythms are regulated by interaction between environmental time cues and the internal circadian timing system. The environmental light-dark cycle interacts with the circadian timing system, and is the major time keeper for the master body clock which regulates many biological rhythms. Non-24 patients frequently struggle with severe disruptions to the sleep-wake cycle when the master body clock is out-of-sync with the 24-hour world.

Vanda Pharmaceuticals, Inc. Reports Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Sales Guidance for the Full Year 2015

Vanda Pharmaceuticals, Inc. reported consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $27,582,000 against $10,862,000 a year ago. Loss from operations was $5,458,000 against $21,606,000 a year ago. Net loss was $5,386,000 or $0.13 per basic and diluted share against $21,575,000 or $0.64 per basic and diluted share a year ago. Non-GAAP net loss was $376,000 or $0.01 per basic and diluted share compared to $27,279,000 or $0.81 per basic and dilute share a year ago. Non-GAAP total revenues were $27,582,000 compared to $3,098,000 a year ago. For the six months, the company reported total revenues of $49,732,000 against $20,005,000 a year ago. Loss from operations was $15,751,000 against $48,184,000 a year ago. Net loss was $15,607,000 or $0.37 per basic and diluted share diluted against $48,108,000 or $1.42 per basic and diluted share a year ago. Net cash used in operating activities was $60,569,000 against $17,168,000 a year ago. Non-GAAP net loss was $4,508,000 or $0.11 per basic and diluted share compared to $59,306,000 or $1.76 per basic and dilute share a year ago. Non-GAAP total revenues were $49,732,000 compared to $4,789,000 a year ago. For the year 2015, the company expected net product sales from both HETLIOZ and Fanapt of between $100 million and $115 million, compared to prior guidance of $95 million to $110 million. The company expected HETLIOZ net product sales of between $40 million to $45 million. The company expected Fanapt net product sales of between $60 million to $70 million, compared to prior guidance of $55 million to $65 million.

Vanda Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:30 PM

Vanda Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 01:30 PM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer and Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VM4:GR €10.63 EUR +0.011

VM4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,252 GBp +135.00
Bristol-Myers Squibb Co $60.39 USD +0.78
Eli Lilly & Co $82.54 USD +0.73
Pernix Therapeutics Holdings Inc $4.70 USD +0.049
Sanofi €89.98 EUR +2.74
View Industry Companies
 

Industry Analysis

VM4

Industry Average

Valuation VM4 Industry Range
Price/Earnings 9.0x
Price/Sales 6.1x
Price/Book 3.3x
Price/Cash Flow 8.1x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.